Company intelligence / Profile preview

MedAutonomic

San Francisco, California, United States

Ownership: Private
Employees: ~10
Development stage: Other

Overview

MedAutonomic is a clinical-stage bioelectronic medicine company developing the Phoenix, an 'Electronic Pill' designed to treat metabolic diseases. The device is a leadless stimulator implanted into the stomach wall via a minimally invasive endoscopic procedure. It works by stimulating the vagus nerve to modulate the autonomic nervous system, aiming to restore metabolic balance. This approach targets conditions such as Type 2 Diabetes and hypertension by leveraging the gut-brain axis. The company's technology offers a potential alternative to lifelong pharmacological treatments for chronic metabolic disorders.

Therapeutic areas: EndocrinologyCardiovascularMetabolic Disorders
Modalities: DeviceBioelectronic medicine
Industry: Therapeutic Medical Devices

Beyond the preview

Go deeper on MedAutonomic.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on MedAutonomic.

Explore the full profile